How to Overcome the AAV Packaging Limit: Split the Cargo or Downsize the Editing Tool?

You have a target gene larger than 6 kb. The vector map is ready, the primers have been designed, and everything seems set for the next step. But when it comes time to package the construct into an adeno-associated virus (AAV) vector, you hit a fundamental limitation: the sequence simply will not fit.

This is not a problem with your experimental technique. It is a physical constraint. The AAV capsid is relatively small and has a well-defined capacity for foreign genetic material. Yet many genes researchers need to deliver exceed the packaging capacity of a single AAV vector. Examples include the DMD gene (~14 kb), ABCA4 (~6.8 kb), MYO7A (~6.7 kb), and the dysferlin cDNA (~6.2 kb).

When faced with this challenge, researchers generally have two options: split the genetic cargo between two vectors or use a smaller genome-editing tool that can fit into a single AAV. Whichever strategy you choose, several important technical considerations are easy to overlook.

The Packaging Limit Is Defined by the ITRs: Approximately 4.7 kb, with Oversized Genomes Prone to Truncation

The commonly cited packaging capacity of AAV is approximately 4.7 kb. This refers to the length of the exogenous DNA sequence that can be accommodated between the two inverted terminal repeats (ITRs). Published estimates vary slightly, generally falling within the 4.5–5.0 kb range, depending on the vector backbone and the size of the expression cassette. There is no need to treat 4.7 kb as an absolute cutoff for every construct.

Why not simply exceed the limit? Because the AAV capsid has a limited, relatively fixed packaging capacity. It does not expand to accommodate an oversized insert. Instead, genomes that exceed the packaging capacity may undergo truncation, resulting in incomplete DNA sequences and an increased proportion of capsids containing incomplete or no vector genomes.

These outcomes can reduce the proportion of functional vector particles, increase production costs, and potentially contribute to unwanted inflammatory or immune responses in vivo.

In other words, the AAV packaging limit cannot simply be overcome by optimizing the production workflow. It fundamentally changes the design strategy: the amount of genetic material packaged into each individual vector must be reduced.

Splitting the Cargo Between Two Vectors: Split Inteins Enable Protein Reconstitution, but Come with Three Trade-Offs

The dual-AAV strategy is straightforward in principle: divide a large genetic payload into two fragments, package each fragment into a separate AAV vector, and deliver both vectors to the same target cell, where the two components can be reconstituted.

One widely studied approach uses split inteins. Each protein fragment is fused to one half of a split intein. Once both components are expressed in the same cell, the intein fragments associate and catalyze protein trans-splicing, removing the intein sequences and joining the two protein fragments through a peptide bond to produce a full-length protein.

The key advantage is that reconstitution occurs at the protein level, without requiring recombination at the DNA level.

However, dual-AAV delivery involves several important trade-offs:

1. Higher total viral dose.

The two vectors must be produced separately and then administered together. Achieving a comparable biological effect may require a higher combined viral dose than a single-vector approach.

2. Both vectors must transduce the same target cell.

If a cell receives only one of the two vectors, it lacks the other component and cannot produce the complete functional protein. This co-transduction requirement is one of the major factors limiting the overall efficiency of dual-AAV systems.

3. Lower overall transduction efficiency and potential dose-limiting toxicity.

Higher doses are often needed to compensate for incomplete co-transduction. However, increasing the viral dose can also increase safety concerns, including dose-dependent toxicity.

Split inteins also have their own limitations. Splicing efficiency is highly dependent on the amino acid sequences surrounding the cleavage and ligation sites. The process may generate inactive truncated byproducts, and additional amino acids can sometimes remain at the junction as unwanted molecular scars. These factors should be considered when selecting a split-intein system.

Where can you source the two vectors and the associated production components?

Miaoling Biotechnology offers a range of AAV-related transfer and packaging helper plasmids in its in-stock plasmid catalog. The collection covers applications ranging from gene expression and gene silencing to gene knockout and viral packaging.

Available packaging-related plasmids include:

· pHelper (P0243)

· pAAV-RC (P0245)

· pAAV-DJ (P2924)

· pAAV2/9n (P12267)

· pAdDeltaF6 (P10945)

These products can be located directly by searching their catalog numbers.

Downsizing the Editing Tool: Compare the Size of Different Editors Before Considering Cas12f Limitations

If the cargo that does not fit is the genome-editing tool itself rather than the target gene, another strategy is to use a smaller editor.

The approximate size ranges of commonly used and emerging genome-editing tools are summarized below:

Among these systems, AsCas12f1, a member of the Cas12f family, contains only 422 amino acids, making it one of the smallest RNA-guided Cas nucleases reported. IscB (~400 amino acids) and TnpB (350–550 amino acids), which are considered ancestral proteins related to Cas9 and Cas12 systems, respectively, are approximately two-fifths the size of Cas9.

The advantage of downsizing is straightforward: compact Cas12 proteins, including Cas12f, Cas12j, and Cas12m, can be delivered using a single AAV vector for DNA editing, eliminating the need to split the editing machinery across two vectors.

However, smaller does not necessarily mean better. Cas12f has two recognized limitations that should be considered:

· Lower cleavage activity: Its double-stranded DNA cleavage activity is generally weaker than that of established Cas9 and Cas12a systems.

· Variable editing performance: Its activity can vary considerably across different genomic target sites.

These limitations are among the reasons why compact genome editors remain an active area of research and development.

In one study, researchers co-packaged a light-activated Cas12f system (psCas12f) and an sgRNA into a single AAV vector. Following activation by focused ultrasound, localized gene editing was achieved in skeletal muscle, the liver, and the brain of mice.

In another study, a single AAV vector was used to deliver SaCas9 targeting the P2ry12 gene in microglia. Expression of the viral vector for 21 days resulted in a significant reduction in P2ry12 expression.

Other studies have explored improvements to both the AAV capsid and its regulatory elements. Through multi-omics screening, researchers identified a 446-bp microglia-specific regulatory element. An engineered AAV2/9.m capsid also showed a substantial increase in production yield compared with its predecessor, with the original study reporting an approximately sevenfold improvement. In addition, miR-9 target sequences were incorporated to reduce off-target expression in neurons. The same body of work also demonstrated that codon optimization can substantially alter the expression level of the same protein.

It is important to note that these findings were obtained in specific mouse models and cell types. They should not be directly extrapolated to other targets, tissues, or therapeutic applications without further validation.

For researchers exploring compact genome-editing systems, Miaoling Biotechnology's in-stock catalog also includes several relevant vector formats, such as:

· pX552 (P0437)

· Nme2Cas9_AAV (P8769)

· pEJS654 (P5593) – All-in-One AAV-sgRNA-hNmeCas9

These products can serve as starting points when searching for suitable vector designs.

Working with AAV Plasmids: ITR Maintenance, Integrity Verification, and Helper Plasmid Selection

Regardless of which delivery strategy you choose, several practical considerations related to AAV plasmids deserve attention during experimental preparation.

Use Recombination-Deficient Bacterial Strains and Grow ITR-Containing Plasmids at 30°C

ITRs are structurally unstable DNA sequences that are prone to rearrangement or deletion during propagation in E. coli.

A common approach is to use recombination-deficient bacterial strains, such as Stbl3, to minimize these events. Culturing the bacteria at a reduced temperature of 30°C can also help reduce replication-associated errors by slowing bacterial growth. The specific strain and culture temperature should be adjusted according to the experimental system.

There is also a counterintuitive detail when selecting colonies: smaller colonies may be worth prioritizing. Clones that have lost their ITR sequences may grow faster than those retaining intact ITRs. Therefore, simply picking the largest colonies does not necessarily yield the desired clones.

Miaoling Biotechnology's in-stock catalog generally specifies two important parameters for AAV-related plasmids: the recommended competent cell strain and the cultivation temperature. Some entries also include the intended application and bacterial host.

Checking these specifications first can help researchers determine how to propagate a given plasmid and whether it is suitable for their experimental needs.

However, matching the recommended bacterial strain and culture temperature does not guarantee that the ITRs in a particular plasmid preparation are intact. ITR integrity must still be experimentally verified.

Verify ITR Integrity by Restriction Digestion, Not Sequencing Alone

A common approach to checking ITR integrity is restriction enzyme digestion followed by analysis of the characteristic DNA banding pattern.

For example, when using XmaI or SmaI, an intact ITR-containing construct may produce a characteristic band of approximately 2.9 kb, together with another band corresponding to the size of the expression cassette.

Why emphasize restriction digestion? Because ITR regions form complex secondary structures that are difficult to read through using conventional Sanger sequencing. A sequencing result that appears normal does not necessarily confirm that the ITRs are intact.

The appropriate restriction enzyme and digestion strategy should be determined according to the specific vector backbone.

This is also an important part of plasmid quality control at Miaoling Biotechnology. Both restriction digestion analysis and sequencing verification are included as formal quality-control procedures.

Do Not Overlook the Helper Plasmids

AAV production commonly uses a three-plasmid co-transfection system consisting of:

· Transfer plasmid: The AAV vector carrying the gene of interest and the corresponding ITRs.

· Helper plasmid: Supplies the adenoviral helper functions required for AAV production.

· Rep/Cap plasmid: Provides the replication and capsid proteins specific to the selected AAV serotype.

The exact plasmid components and their quantities depend on the production system being used.

Therefore, after obtaining the transfer vector, researchers should also confirm that all corresponding helper plasmids are available and compatible with the selected system.

Miaoling Biotechnology's Plasmid Handbook groups these specialized products under the category of Viral Vector Plasmid Systems in its quick-reference table, providing a convenient resource for reviewing the components required for different experimental workflows.

Choosing the Right Strategy: Consider Cargo Size, Target Tissue, and Required Expression Duration

These two approaches are not mutually exclusive, nor is one universally better than the other. Each involves a different set of trade-offs.

· Dual-AAV delivery increases packaging capacity at the cost of higher total viral doses and the need for efficient co-transduction.

· Compact genome editors make single-AAV delivery possible but may involve trade-offs in editing activity, efficiency, and performance across different target sites.

The right choice depends on the size of the genetic cargo, the target tissue, and how long the system needs to remain active.

Before starting an experiment, there is one important check researchers can perform themselves: when working with an AAV-related plasmid, first inspect the vector map to confirm the integrity of the ITRs and calculate the total sequence length between them. Many packaging-related issues can be identified at this stage, before moving on to vector production.

According to Hubei Daily, an approved gene therapy for hemophilia B in China uses an AAV vector to deliver the coagulation factor gene into patients. This is a practical example of how plasmid-based AAV packaging supports the development of gene therapies.

If you have completed the checks outlined above but still cannot identify the source of the problem, you can contact the Miaoling Biotechnology technical support team for further assistance with troubleshooting.

https://www.miaolingbio.net
Wuhan MiaoLing Biotechnology Co., Ltd.

About Author

admin

See author's posts